Related Experiment Video
Updated: May 31, 2025
06:11
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
9.7K
Predicting Early Death in Head and Neck Cancer-A Pilot Study
Charbél Talani1,2, Hans Olsson3, Karin Roberg2,4
1Division of Sensory Organs and Communication, Department of Biomedical and Clinical Sciences, Linköping University, 581 83 Linköping, Sweden.
Cancers
|January 25, 2025
Summary
Head and neck cancer (HNC) patients with high Ki67 and survivin expression in tumor biopsies face a greater risk of early death. These biomarkers may aid in predicting prognosis and guiding treatment decisions.
Area of Science:
- Oncology
- Biomarker Research
- Cancer Diagnostics
Background:
- Head and neck cancer (HNC) poses a significant mortality risk.
- Accurate prognostication is crucial for effective HNC management.
- Identifying reliable biomarkers for early death risk in HNC is an unmet clinical need.
Purpose of the Study:
- To evaluate tumor biopsy biomarkers and biological characteristics in HNC patients.
- To assess the risk of early mortality within six months of diagnosis.
- To determine if marker combinations can prognosticate early death in HNC.
Main Methods:
- Retrospective analysis of HNC patients.
- Inclusion of patients who died within six months of diagnosis and matched survivors (at least two years).
- Comparison of marker expression (Ki-67, survivin) between early-death and survivor groups.
Main Results:
- Significantly higher Ki-67 expression in early-death patients (mean difference 21%, p=0.038).
- Increased cytoplasmic survivin expression in early-death patients (p=0.021).
- Significant difference in survivin staining intensity between groups (p=0.006).
Conclusions:
- Ki67 and survivin show potential as prognostic biomarkers for early death in HNC.
- These markers may be valuable additions to prognostic panels for HNC treatment decisions.
- This pilot study highlights the need for further validation of these biomarkers.
